A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib

This Phase 2 study tests a combination of two targeted cancer drugs — avutometinib and defactinib — for women with gynecological cancers (including ovarian, endometrial, and other solid gynecological cancers) that have specific gene mutations (RAS, BRAF, or NF-1). These mutations make cancer cells grow in a certain way that may be blocked by this drug combination. **You may be eligible if...** - You are a woman aged 18 or older - You have been diagnosed with a gynecological cancer (such as ovarian, endometrial, or mucinous ovarian carcinoma) - Your tumor has been tested and found to have mutations in RAS, BRAF, NF-1, or related pathways - You have received prior treatment and your cancer has progressed or returned - Archival tumor tissue is available for testing **You may NOT be eligible if...** - Your tumor does not have the required mutations - You have significant liver, heart, or lung problems - You have uncontrolled brain metastases - You are pregnant or breastfeeding - You have received prior treatment with MEK inhibitors or FAK inhibitors Talk to your doctor to see if this trial is right for you.